Welcome to our dedicated page for Disc Medicine news (Ticker: $IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Disc Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Disc Medicine's position in the market.
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ: IRON) announced positive topline data from the AURORA phase 2 study of bitopertin in patients with EPP. The study demonstrated dose-dependent reductions in PPIX, improvements in light tolerance, and reductions in phototoxic reactions with pain. Bitopertin showed statistical significance at the 60 mg dose group compared to placebo on various endpoints. Despite strong performance, the cumulative time in sunlight on days without pain did not meet statistical significance due to placebo response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.05%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) reported positive results from the AURORA phase 2 study of bitopertin in erythropoietic porphyrias (EPP) and provided updates on DISC-0974 and DISC-3405 programs. The company strengthened its leadership team and ended 2023 with approximately $360M in cash. Key financial data for 2023 showed an increase in cash position, higher R&D and G&A expenses, and a net loss of $76.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) to participate in a fireside chat at Leerink Partners Global Biopharma Conference 2024, showcasing their focus on novel treatments for hematologic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
Rhea-AI Summary
Disc Medicine, Inc. appoints Pamela Stephenson as Chief Commercial Officer, bringing over 25 years of biopharma commercial leadership experience to lead global commercialization efforts for novel hematologic treatments. Ms. Stephenson's track record includes successful global launches for rare disease therapies, positioning Disc for growth and late-stage development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) receives Fast Track Designation from the FDA for DISC-0974 in the treatment of NDD-CKD patients with anemia, showcasing potential for addressing unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) receives Orphan Drug Designation from the FDA for DISC-3405 in treating polycythemia vera, a rare hematologic disease. The designation signifies potential benefits and support for the ongoing Phase 1 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
Rhea-AI Summary
Disc Medicine, Inc. appoints Jean Franchi as Chief Financial Officer and promotes Jonathan Yu to Chief Operating Officer. Franchi brings over 30 years of finance leadership experience in biotech companies, and Yu has been involved in key business roles at the company. The company expresses excitement about important data read-outs for their programs in 2024 and the potential for late-stage development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) announced the retirement of Chief Innovation Officer, Dr. Brian MacDonald, after a distinguished 28-year career. Dr. MacDonald will transition to become Chair of Disc’s Scientific Advisory Board. The company expressed gratitude for his leadership and contributions, with plans for him to continue leading as part of the Scientific Advisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Rhea-AI Summary
Disc Medicine, Inc. (NASDAQ:IRON) presented updated results from the phase 2 open-label BEACON study of bitopertin, an orally administered glycine transporter 1 (GlyT1) inhibitor, in patients with erythropoietic protoporphyria (EPP) as an oral presentation at the 65th ASH Annual Meeting. The data showed significant reductions in protoporphyrin IX (PPIX) > 40%, improvements in sunlight tolerance, and positive results from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
Disc Medicine, Inc.
Nasdaq:IRON
IRON Rankings
IRON Stock Data
742.63M
13.49M
13.38%
84.99%
7.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
WATERTOWN
About IRON
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.